Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

This study has been completed.
Ambit Biosciences Corporation
Information provided by (Responsible Party):
Therapeutic Advances in Childhood Leukemia Consortium Identifier:
First received: August 1, 2011
Last updated: May 17, 2013
Last verified: May 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2013
  Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)